Josephine van Dongen

Chapter 8 202 prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: Case-control study. BMJ . Published online 2012. doi:10.1136/bmj.e4752 37. Cor tese MM, Immergluck CL,Held M, et al. Effectiveness of Monovalent and Pentavalent rotavirus vaccine. Pediatrics. 2013;7(1):13-20. doi:10.5152/ced.2013.04 38. Payne DC, Boom JA, Staat MA, et al. Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009-2011. HHS Public Heal . 2013;57(1):13-20. doi:10.1093/cid/cit164.Effectiveness 39. Rose A, Kissling E, Emborg HD, et al. Interim 2019/20 influenza vaccine effectiveness: Six European studies, September 2019 to January 2020. Eurosurveillance . 2020;25(10):1-14. doi:10.2807/1560-7917.ES.2020.25.10.2000153 40. Pebody RG, Zhao H,Whitaker HJ, et al. Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England. Vaccine . 2020;38(2):158-164. doi:10.1016/j.vaccine.2019.10.035 41. Arkema JM, Meijer A, Meerhoff TJ, Van Der Velden J, Paget WJ. Epidemiological and virological assessment of influenza activity in Europe, during the 2006-2007 winter. Euro Surveill. 2008;13(34):1-7. doi:10.2807/ese.13.34.18958-en 42. Tate JE, Haynes A, Payne DC, et al.Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000 to 2012. Pediatr Infect Dis J . 2013;32(7):741-744. doi:10.1097/INF.0b013e31828d639c 43. EuroRotaNet. NoTitle. Accessed January 9, 2018. http://www.eurorota.net/ 44. Lee B. Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines. HumVaccines Immunother. 2020;00(00):1-16. doi:10. 1080/21645515.2020.1844525 45. Chernikova DA, Madan JC, Housman ML, et al.The premature infant gut microbiome during the first 6 weeks of life differs based on gestational maturity at bir th. Pediatr Res. 2018;84(1):71-79. doi:10.1038/s41390-018-0022-z 46. Baxter D. Impaired functioning of immune defences to infection in premature and term infants and their implications for vaccination. Hum Vaccin. Published online 2010. doi:10.4161/ hv.6.6.12008 47. Pagano JS, Plotkin SA, Cornely D. The response of premature infants with type 3 attenuated poliovirus. J Pediatr . 1994;65(2):12337-12343. 48. Keller R, Dwyer JE, Oh W, D’Amodio M. Intestinal IgA neutralizing antibodies in newborn infants following poliovirus immunization. Pediatrics. 1996;43(3):330-339. 49. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis . 2013;208(2):284-294. doi:10.1093/infdis/jit166 50. Burke RM,Tate JE, Kirkwood CD, Steele AD, Parashar UD. Current and new rotavirus vaccines. Curr Opin Infect Dis . 2019;32(5):435-444. doi:10.1097/QCO.0000000000000572 51. Rouers EDM, Bruijning-Verhagen PCJ, van Gageldonk PGM, van Dongen JAP, Sanders EAM, Berbers GAM. Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants. Jama . 2020;324(11):1068-1077. doi:10.1001/jama.2020.12316 52. Benn CS, Netea MG, Selin LK, Aaby P. A Small Jab - A Big Effect: Nonspecific Immunomodulation By Vaccines. Trends Immunol. 2013;34(9):431-439. doi:10.1016/j. it.2013.04.004 53. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375-388. doi:10.1038/s41577-020- 0285-6